CN115212345A - 一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 - Google Patents
一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 Download PDFInfo
- Publication number
- CN115212345A CN115212345A CN202210633194.3A CN202210633194A CN115212345A CN 115212345 A CN115212345 A CN 115212345A CN 202210633194 A CN202210633194 A CN 202210633194A CN 115212345 A CN115212345 A CN 115212345A
- Authority
- CN
- China
- Prior art keywords
- solution
- natural polysaccharide
- polyphenol
- polysaccharide
- hydrogel dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 58
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 58
- 239000000017 hydrogel Substances 0.000 title claims abstract description 53
- 150000004676 glycans Chemical class 0.000 title claims abstract description 44
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 36
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- -1 aldehyde polysaccharide Chemical class 0.000 claims abstract description 19
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 19
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000035876 healing Effects 0.000 claims abstract description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 125000003172 aldehyde group Chemical group 0.000 claims description 8
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 150000002009 diols Chemical group 0.000 claims description 6
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 4
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 claims description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001263 FEMA 3042 Substances 0.000 claims description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 4
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical group OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 4
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 4
- 235000015523 tannic acid Nutrition 0.000 claims description 4
- 229920002258 tannic acid Polymers 0.000 claims description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 4
- 229940033123 tannic acid Drugs 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 2
- MKPDAJWEBQRQCO-UHFFFAOYSA-N (4-aminophenyl)boronic acid Chemical compound NC1=CC=C(B(O)O)C=C1 MKPDAJWEBQRQCO-UHFFFAOYSA-N 0.000 claims description 2
- ZSKXYSCQDWAUCM-UHFFFAOYSA-N 1-(chloromethyl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1CCl ZSKXYSCQDWAUCM-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 2
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 229930000755 gossypol Natural products 0.000 claims description 2
- 229950005277 gossypol Drugs 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 239000000252 konjac Substances 0.000 claims description 2
- 235000019823 konjac gum Nutrition 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 2
- 229920002414 procyanidin Polymers 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 239000002262 Schiff base Substances 0.000 abstract 1
- 150000004753 Schiff bases Chemical class 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 230000029663 wound healing Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003623 transition metal compounds Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/15—Heterocyclic compounds having oxygen in the ring
- C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
- C08K5/1545—Six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用，属于生物医用材料领域。本发明的技术方案要点为：首先是具有邻二醇结构的天然多糖被高碘酸钠氧化得到醛基多糖，然后与接枝有抗菌、抗氧化基团的氨基天然多糖衍生物复合，通过形成Schiff碱交联即可得到多功能水凝胶材料。本发明通过对天然多糖的功能化接枝改性，从而赋予水凝胶内在的多功能性，避免了抗菌等药物使用带来的耐药性问题，在长效促进复杂创面愈合方面具有重要的应用价值。
Description
技术领域
本发明属于生物医用材料技术领域，具体涉及一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用。
背景技术
皮肤创伤，主要包括急性创伤和慢性炎症，这些创伤给患者们带来了各种各样的问题。 皮肤的创伤会导致皮肤丧失某些重要功能，特别是损伤保护人体免受外部致病环境的屏障，从而导致出血和感染，并且会延迟伤口愈合过程。在这个过程中，就需要一些紧急的治疗措施，例如止血、消炎、皮肤细胞的快速增殖和重塑，有利于加速伤口愈合，恢复百分之百的正常皮肤功能。迄今为止，人们已经研发出各种各样的伤口敷料。在诸多类型的伤口敷料中，水凝胶敷料具有独特的优势，其可以保持伤口处的湿润，多孔结构不仅有利于营养物质的传输，还可吸收伤口部位的渗出液等。水凝胶作为一种良好的载体，可以负载抗生素及过渡金属化合物纳米材料等，用以实现特定功能以促进伤口愈合；但是该方法会产生耐药性等副作用，而设计制备具有内在多功能性的水凝胶伤口敷料在临床应用方面具有重要的意义。
公开号为CN108976758A的发明创造公开了一种光敏性的聚乙二醇基抗菌水凝胶敷料及其制备方法，该水凝胶敷料以聚乙二醇为基材，通过光敏性共价键将硫酸庆大霉素接枝到凝胶网络中，并可实现药物在创面处的紫外光响应性释放。该聚乙二醇基水凝胶敷料具有良好的抗菌性能，并可以实现高校便捷的光响应操作。然而该方法制得的聚乙二醇基抗菌水凝胶是通过负载抗生素来实现抗菌功能，长期使用会产生耐药性等副作用，在伤口愈合等生物医用材料领域有必要对伤口敷料进行改进。
发明内容
本发明的目的在于针对现有水凝胶敷料存在的不足，提供了一种多酚交联天然多糖基具水凝胶敷料及其制备方法，该水凝胶敷料具有内在的有抗菌、抗氧化、促愈合的多功能性。具体方法是将苯硼酸接枝的天然多糖与天然多酚通过硼酸酯交联得到多功能水凝胶敷料；天然多酚不仅赋予了该水凝胶抗菌、抗氧化性能，其还赋予了水凝胶组织粘附性，能够较好地作为医用水凝胶伤口敷料应用于促进创伤愈合。
本发明为实现上述目的采用如下技术方案，一种多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于具体步骤为：
步骤S1：将含有氨基的天然多糖或含有醛基的天然多糖溶于去离子水中得到氨基多糖溶液或醛基多糖溶液，其中含有氨基的天然多糖为壳聚糖、羧甲基壳聚糖、羧乙基壳聚糖或羟乙基壳聚糖中的一种或多种；
步骤S2：将3-甲酰基苯硼酸或4-甲酰基苯硼酸加入到步骤S1得到的氨基多糖溶液中并于室温搅拌至全部溶解得到溶液A，或者将3-氨基苯硼酸或4-氨基苯硼酸加入到步骤S1得到的醛基多糖溶液中并于室温搅拌至全部溶解得到溶液B；
步骤S3：将天然多酚溶于去离子水中得到多酚溶液，其中天然多酚为原花青素、表没食子儿茶素没食子酸酯、表没食子儿茶素、表儿茶酚没食子酸、单宁酸、鞣花酸、芦丁或棉酚中的一种或多种；
步骤S4：将步骤S2得到的溶液A或溶液B与步骤S3得到的多酚溶液混匀，再于室温静置即可得到具有内在抗菌、抗氧化、促愈合功能性的多酚交联天然多糖基水凝胶敷料。
进一步限定，步骤S1中所述含有醛基的天然多糖的具体制备过程为：
步骤S101：将含有邻二醇结构的天然多糖溶于去离子水中得到含有邻二醇结构的天然多糖溶液，其中含有邻二醇结构的天然多糖为海藻酸钠、透明质酸钠、魔芋胶、瓜尔豆胶、***树胶、葡聚糖、纤维素、硫酸软骨素或肝素中的一种或多种；
步骤S102：将高碘酸钠溶于去离子水中得到高碘酸钠溶液；
步骤S103：将步骤S102得到的高碘酸钠溶液加入到步骤S101得到的含有邻二醇结构的天然多糖溶液中混匀，于室温下避光搅拌反应，再向反应液中加入乙二醇继续反应，反应完成后将反应液装入透析袋，放入去离子水中透析后冻干得到含有醛基的天然多糖。
进一步限定，步骤S103中所述高碘酸钠与含有邻二醇结构的天然多糖的摩尔比为0.2~2:1。
进一步限定，步骤S1中所述氨基多糖溶液或醛基多糖溶液的浓度为2~150mg/mL。
进一步限定，步骤S2中所述3-甲酰基苯硼酸或4-甲酰基苯硼酸与氨基多糖溶液中氨基的摩尔比为0.05~0.2:1，3-氨基苯硼酸或4-氨基苯硼酸与醛基多糖溶液中醛基的摩尔比为0.05~0.4:1。
进一步限定，步骤S3中所述多酚溶液的浓度为5~100mg/mL。
进一步限定，步骤S4中所述溶液A或溶液B与多酚溶液的投料配比满足：步骤S2得到的溶液A或溶液B中苯硼酸基团和步骤S3得到的多酚溶液中邻二醇基团的摩尔比为2~6:1。
本发明所述的多酚交联天然多糖基水凝胶敷料，其特征在于是基于上述方法制得的。
本发明所述的多酚交联天然多糖基水凝胶敷料在制备生物医用敷料中的应用。
本发明与现有技术相比具有以下优点和有益效果：本发明提供的具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料包含生物相容性良好的天然多糖和提供多功能性的天然多酚，避免了传统水凝胶敷料通过负载抗菌、抗炎药物实现多功能的耐药性等缺点，具有优异的促进创面愈合的作用。
附图说明
图1是本发明实施例3制备的水凝胶敷料冻干后的扫描电子显微镜图；
图2是本发明实施例3制备的水凝胶敷料的抗菌性能测试结果；
图3是本发明实施例3制备的水凝胶敷料的抗氧化性测试结果；
图4是本发明实施例3制备的水凝胶敷料在小鼠皮肤全层伤口实验第14天时伤口组织的HE染色图。
具体实施方式
以下通过实施例对本发明的上述内容做进一步详细说明，但不应该将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明上述内容实现的技术均属于本发明的范围。
实施例1
步骤S1：将0.25g羟乙基壳聚糖溶于5mL去离子水中得到羧甲基壳聚糖溶液；
步骤S2： 将4.5mg 4-甲酰基苯硼酸加入到步骤S1所得溶液中室温下搅拌至全部溶解；
步骤S3：将50mg原花青素溶于5mL去离子水中得到原花青素溶液；
步骤S4：将步骤S2得到的溶液与步骤S3得到溶液等体积混匀，于室温下静置180min得到具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料。
实施例2
步骤S1：将0.32g醛基透明质酸钠溶于4mL去离子水中得到醛基透明质酸钠溶液；
步骤S2：将4mg 3-氨基苯硼酸加入到步骤S1所得溶液中室温下搅拌至全部溶解；
步骤S3：将60mg表没食子儿茶素没食子酸酯溶于4mL去离子水中得到表没食子儿茶素没食子酸酯溶液；
步骤S4：将步骤S2得到的溶液与步骤S3得到溶液按照体积比1:0.8混匀，于室温下静置300min得到具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料。
实施例3
步骤S1：将0.3g羧甲基基壳聚糖溶于5mL去离子水中得到羧甲基壳聚糖溶液；
步骤S2：将5mg 4-甲酰基苯硼酸加入到步骤S1所得溶液中室温下搅拌至全部溶解；
步骤S3：将0.15g单宁酸溶于5mL去离子水中得到单宁酸溶液；
步骤S4：将步骤S2得到的溶液与步骤S3得到溶液按照体积比1:1.2混匀，于室温下静置30min得到具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料。
为了说明本发明提供的具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料的各项性能，对实施例3制备的具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料进行测试，测试结果见图1～4。
图1为实施例3制备的水凝胶敷料冻干后的扫描电子显微镜图，可以观察到三维网状凝胶骨架结构。
图2为实施例3制备的水凝胶敷料的抗菌性能测试结果，如图所示，相对于空白对照组，制备的多功能水凝胶敷料对革兰氏阴性的大肠杆菌和革兰氏阳性的金黄色葡萄球菌展现出优异的抗菌性能。
图3为实施例3制备的水凝胶敷料的抗氧化性测试结果，如图所示，制备的多功能水凝胶敷料对ABTS+自由基展现出良好的清除能力。
图4为实施例3制备的水凝胶敷料在小鼠皮肤全层伤口实验第14天时伤口组织的HE染色图，相对于空白对照组，制备的多功能水凝胶敷料组具有较多的毛孔、血管等较为完整的皮肤组织和附属器官，证明了所制备多功能水凝胶敷料具有良好的促进伤口愈合的性能。
综上，本发明提供的具有内在抗菌、抗氧化、促愈合等多功能性的水凝胶敷料展现出良好的抗菌、抗氧化等性能，并在小鼠皮肤全层伤口实验中，能够促进较为完整的皮肤组织及其附属器官从而加速伤口的愈合。
以上显示和描述了本发明的基本原理、主要特征和优点，在不脱离本发明精神和范围的前提下，本发明还有各种变化和改进，这些变化和改进都要求落入本发明的保护范围之内。
Claims (9)
1.一种多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于具体步骤为：
步骤S1：将含有氨基的天然多糖或含有醛基的天然多糖溶于去离子水中得到氨基多糖溶液或醛基多糖溶液，其中含有氨基的天然多糖为壳聚糖、羧甲基壳聚糖、羧乙基壳聚糖或羟乙基壳聚糖中的一种或多种；
步骤S2：将3-甲酰基苯硼酸或4-甲酰基苯硼酸加入到步骤S1得到的氨基多糖溶液中并于室温搅拌至全部溶解得到溶液A，或者将3-氨基苯硼酸或4-氨基苯硼酸加入到步骤S1得到的醛基多糖溶液中并于室温搅拌至全部溶解得到溶液B；
步骤S3：将天然多酚溶于去离子水中得到多酚溶液，其中天然多酚为原花青素、表没食子儿茶素没食子酸酯、表没食子儿茶素、表儿茶酚没食子酸、单宁酸、鞣花酸、芦丁或棉酚中的一种或多种；
步骤S4：将步骤S2得到的溶液A或溶液B与步骤S3得到的多酚溶液混匀，再于室温静置即可得到具有内在抗菌、抗氧化、促愈合功能性的多酚交联天然多糖基水凝胶敷料。
2.根据权利要求1所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于步骤S1中所述含有醛基的天然多糖的具体制备过程为：
步骤S101：将含有邻二醇结构的天然多糖溶于去离子水中得到含有邻二醇结构的天然多糖溶液，其中含有邻二醇结构的天然多糖为海藻酸钠、透明质酸钠、魔芋胶、瓜尔豆胶、***树胶、葡聚糖、纤维素、硫酸软骨素或肝素中的一种或多种；
步骤S102：将高碘酸钠溶于去离子水中得到高碘酸钠溶液；
步骤S103：将步骤S102得到的高碘酸钠溶液加入到步骤S101得到的含有邻二醇结构的天然多糖溶液中混匀，于室温下避光搅拌反应，再向反应液中加入乙二醇继续反应，反应完成后将反应液装入透析袋，放入去离子水中透析后冻干得到含有醛基的天然多糖。
3.根据权利要求2所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于：步骤S103中所述高碘酸钠与含有邻二醇结构的天然多糖的摩尔比为0.2~2:1。
4.根据权利要求1所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于：步骤S1中所述氨基多糖溶液或醛基多糖溶液的浓度为2~150mg/mL。
5.根据权利要求1所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于：步骤S2中所述3-甲酰基苯硼酸或4-甲酰基苯硼酸与氨基多糖溶液中氨基的摩尔比为0.05~0.2:1，3-氨基苯硼酸或4-氨基苯硼酸与醛基多糖溶液中醛基的摩尔比为0.05~0.4:1。
6.根据权利要求1所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于：步骤S3中所述多酚溶液的浓度为5~100mg/mL。
7.根据权利要求1所述的多酚交联天然多糖基水凝胶敷料的制备方法，其特征在于步骤S4中所述溶液A或溶液B与多酚溶液的投料配比满足：步骤S2得到的溶液A或溶液B中苯硼酸基团和步骤S3得到的多酚溶液中邻二醇基团的摩尔比为2~6:1。
8.一种多酚交联天然多糖基水凝胶敷料，其特征在于是基于权利要求1~7中任意一项所述的方法制得的。
9.权利要求8所述的多酚交联天然多糖基水凝胶敷料在制备生物医用敷料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210633194.3A CN115212345A (zh) | 2022-06-07 | 2022-06-07 | 一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210633194.3A CN115212345A (zh) | 2022-06-07 | 2022-06-07 | 一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115212345A true CN115212345A (zh) | 2022-10-21 |
Family
ID=83608723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210633194.3A Pending CN115212345A (zh) | 2022-06-07 | 2022-06-07 | 一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115212345A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115970040A (zh) * | 2022-12-16 | 2023-04-18 | 北京科技大学 | 可黏结湿表面且易更换促修复的水凝胶敷贴及其制备方法 |
| CN117159786A (zh) * | 2023-08-30 | 2023-12-05 | 广州贝奥吉因生物科技股份有限公司 | 用于再生伤口愈合的壳聚糖水凝胶的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150000561A1 (en) * | 2012-02-28 | 2015-01-01 | Contipro Biotech S.R.O. | Derivates Based on Hyaluronic Acid, Capable of Forming Hydrogels, Method of Preparation Thereof, Hydrogels Based on Said Derivatives, Method of Preparation Thereof and Use |
| CN108175765A (zh) * | 2017-12-01 | 2018-06-19 | 东南大学 | 一种酸敏控释抗炎凝胶及其制备方法与应用 |
| DE102017222072A1 (de) * | 2017-12-06 | 2019-06-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Hydrogel mit antioxidativer Wirkung |
| CN114432488A (zh) * | 2022-03-07 | 2022-05-06 | 中南大学 | 一种双重动态化学键交联的自愈合可注射水凝胶、制备方法及其应用 |
-
2022
- 2022-06-07 CN CN202210633194.3A patent/CN115212345A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150000561A1 (en) * | 2012-02-28 | 2015-01-01 | Contipro Biotech S.R.O. | Derivates Based on Hyaluronic Acid, Capable of Forming Hydrogels, Method of Preparation Thereof, Hydrogels Based on Said Derivatives, Method of Preparation Thereof and Use |
| CN108175765A (zh) * | 2017-12-01 | 2018-06-19 | 东南大学 | 一种酸敏控释抗炎凝胶及其制备方法与应用 |
| DE102017222072A1 (de) * | 2017-12-06 | 2019-06-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Hydrogel mit antioxidativer Wirkung |
| CN114432488A (zh) * | 2022-03-07 | 2022-05-06 | 中南大学 | 一种双重动态化学键交联的自愈合可注射水凝胶、制备方法及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| QINGCONG WEI ET AL * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115970040A (zh) * | 2022-12-16 | 2023-04-18 | 北京科技大学 | 可黏结湿表面且易更换促修复的水凝胶敷贴及其制备方法 |
| CN117159786A (zh) * | 2023-08-30 | 2023-12-05 | 广州贝奥吉因生物科技股份有限公司 | 用于再生伤口愈合的壳聚糖水凝胶的制备方法 |
| CN117159786B (zh) * | 2023-08-30 | 2024-03-26 | 广州贝奥吉因生物科技股份有限公司 | 用于再生伤口愈合的生物活性水凝胶的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Chitin and chitosan: biopolymers for wound management | |
| Zheng et al. | Self-healing polysaccharide-based injectable hydrogels with antibacterial activity for wound healing | |
| Wang et al. | Preparation of antimicrobial hyaluronic acid/quaternized chitosan hydrogels for the promotion of seawater-immersion wound healing | |
| CN115212345A (zh) | 一种多酚交联天然多糖基水凝胶敷料及其制备方法和应用 | |
| Moura et al. | Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review | |
| Cui et al. | Polysaccharide-based hydrogels for wound dressing: Design considerations and clinical applications | |
| CN110314242B (zh) | 一种可控释放的抗生素复合水凝胶的制备方法及其用途 | |
| EP1305355A1 (en) | Hydrogel films and methods of making and using therefor | |
| WO2014161085A1 (en) | Schiff-based aldehydic hyaluronic acid-chitosan hydrogel compositions and uses thereof | |
| Kumar et al. | Recent advances in the use of algal polysaccharides for skin wound healing | |
| CN113372585A (zh) | 一种具有高粘附性复合功能水凝胶的制备方法及其应用 | |
| WO2008157285A1 (en) | Biopolymer based implantable degradable devices | |
| CN111234266A (zh) | 一种壳聚糖/聚乙烯醇水凝胶敷料的制备方法 | |
| CN115926200A (zh) | 一种酶催化双交联高分子复合水凝胶材料的制备方法及应用 | |
| CN113425893A (zh) | 一种载药水凝胶的制备方法及其应用 | |
| CN107252501A (zh) | 一种负载血根碱/明胶微球的复合水凝胶支架及其制备方法和应用 | |
| CN113214507A (zh) | 一种抗菌糖肽水凝胶的制备方法 | |
| CN113817181A (zh) | 一种碳量子点修饰的双网络水凝胶及其制备方法 | |
| CN115068684A (zh) | 用于糖尿病慢性创面修复的载姜黄素水凝胶及其制备方法 | |
| CN112979995B (zh) | 一种含银水凝胶及其制备方法与应用 | |
| Chen et al. | Mussel-inspired self-healing hydrogel form pectin and cellulose for hemostasis and diabetic wound repairing | |
| CN113509591A (zh) | 一种抗菌阳离子可注射水凝胶敷料及其制备方法 | |
| CN115382008B (zh) | 一种适用于糖尿病创面修复的可注射水凝胶的制备方法 | |
| CN114539558A (zh) | 一种具有内在抗菌、抗氧化、粘附性水凝胶材料及其制备方法和应用 | |
| CN114479124B (zh) | 一种可自愈水凝胶、其制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221021 |
|
| WD01 | Invention patent application deemed withdrawn after publication |